UK markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6000+0.1400 (+5.69%)
As of 03:26PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.4600
Bid2.6000 x 1800
Ask2.6100 x 1200
Day's range2.4650 - 2.6350
52-week range1.3800 - 9.7400
Avg. volume6,980,819
Market cap648.44M
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)-1.5420
Earnings date07 Nov 2022 - 11 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.20
  • Motley Fool

    Why Inovio Pharmaceuticals Is Gaining Today

    Inovio Pharmaceuticals' (NASDAQ: INO) stock rose by more than 18.5% as of 2:30 p.m. ET on Wednesday after the company's Q2 earnings results broke the news of its plans to restructure its operations to conserve cash. The biotech will lay off 18% of its full-time employees while additionally reducing its contractor head count by a massive 86%. Inovio also announced the appointment of a new chief medical officer, Dr. Michael Sumner, which might be another contributing factor to the gain of its stock today.

  • Motley Fool

    Inovio Pharmaceuticals (INO) Q2 2022 Earnings Call Transcript

    Good afternoon, and thank you for joining the Inovio second quarter 2022 financial results conference call. Joining me today on today's call are Dr. Jacque Shea, president and CEO; Mr. Peter Kies, chief financial officer; Dr.

  • Zacks

    Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

    Inovio (INO) delivered earnings and revenue surprises of -53.33% and 264.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?